ALEXANDRIA, Va. - An update of the American Society of Clinical Oncology (ASCO) clinical practice guideline clarifies the role of immunotherapy in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The update also provides new recommendations on the use of targeted therapies for patients with changes in tumor EGFR, ALK, and ROS1 genes.
Researchers found that the survival rate of patients with advanced cancer who have cardiac arrest in a hospital setting is about half that of patients without advanced cancer. Although patients in the study with advanced cancer more frequently had “do not resuscitate” orders after their cardiac arrest than those without advanced cancer (55.6% versus 43%), this does not fully explain the survival differences. This new study was published today in the Journal of Oncology Practice (JOP).
ALEXANDRIA, Va. - An update of the American Society of Clinical Oncology (ASCO) clinical practice guideline covers new medicines for nausea and vomiting related to cancer treatment. The update, issued today, provides new evidence-based information on the appropriate use of olanzapine, NK1 receptor antagonists and dexamethasone.
Leading national cancer organizations have released a joint position statement to guide the future of cancer health disparities research. The statement represents a unified strategy by the American Association for Cancer Research (AACR), the American Cancer Society (ACS), the American Society of Clinical Oncology (ASCO), and the National Cancer Institute (NCI) to foster cooperation across the cancer research community to ensure that all patients — regardless of social demographics, socioeconomic status, or the communities in which they live — benefit from cancer research.
The American Society of Clinical Oncology (ASCO) today issued a position statement aimed at contributing to the national dialogue on rising cancer drug prices. The statement, which asserts that any solutions must also preserve patients' access to care and foster innovation, analyzes a wide array of options and recommends that a panel of stakeholders be established to determine which proposals will be effective and develop a uniform approach for assessing the value of drugs.
ALEXANDRIA, Va. — As part of a collaborative program between CancerLinQ LLC and the Oncology Nursing Society (ONS) aimed at helping oncology practices successfully incorporate electronic health record (EHR) data into clinical operations, three ONS members completed training in June to serve in the CancerLinQ® Ambassadors Pilot Program. CancerLinQ, a health information technology platform that powerfully connects and analyzes real-world cancer care data from almost any electronic record source, provides oncologists, nurses, and other practice staff with near real-time, actionable data to improve patient care processes and outcomes.
The American Society of Clinical Oncology (ASCO) remains opposed to the revised Better Care Reconciliation Act (BCRA). Despite the changes to the legislation, released by the Senate yesterday, the bill runs counter to ASCO’s core mission, which is to ensure that patients with cancer have meaningful access to high-quality care. Moreover, it fails to meet with ASCO’s guiding principles for health reform by cutting Medicaid and eroding critical patient protections.
ALEXANDRIA, Va. - New recommendations on the use of the MammaPrint genomic test issued today will help guide decisions on adjuvant systemic therapy for women with early breast cancer. The recommendations update the American Society of Clinical Oncology (ASCO) 2016 clinical practice guideline on the use of biomarkers in these patients.
ALEXANDRIA, Va. -- CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that Ascension has signed an agreement to participate in the CancerLinQ® platform. Ascension, the largest non-profit health system in the United States, includes oncology care facilities throughout the country that can benefit from CancerLinQ’s growing quality network.
ASCO opposes the Better Care Reconciliation Act of 2017, the Senate healthcare bill released today, and urges lawmakers to reject the measure and work on an alternative that provides key protections for patients with cancer. We are disappointed that the legislation fails to meet our guiding principles for healthcare reform by halting Medicaid expansion, reinstating annual and lifetime coverage caps, and cutting coverage for essential health benefits including cancer screening.
“Today, the delegates of the American Medical Association (AMA) voted for Barbara McAneny, MD, FASCO, MACP, as the organization’s President-elect, making her the first oncologist elected to serve in this important leadership position. In our national dialogue on access to health care, patients with cancer often highlight the broader challenges facing the entire system. The awareness Dr. McAneny brings, as an oncologist at the helm of the largest physician association, will benefit patients and providers broadly. On behalf of the American Society of Clinical Oncology (ASCO), I offer my congratulations to my friend and colleague, Dr. McAneny."
The American Society of Clinical Oncology (ASCO) congratulates Dr. Norman "Ned" Sharpless on his appointment as director of the National Cancer Institute (NCI). ASCO is encouraged that NCI will have at its helm an accomplished researcher with experience leading a wide range of clinical and translational research endeavors focused on bringing new insights into cancer prevention and treatment.
IRVING, Texas– Caris Life Sciences®, a leading innovator in molecular science, and the American Society of Clinical Oncology, Inc. (ASCO®), today announced that Caris is one of the first laboratories to have a test report optimized for ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR™) Study. The TAPUR Study is evaluating efficacy of treatments based on patients’ tumor genetic profiles. This designation indicates that the company’s proprietary Caris Molecular Intelligence® comprehensive genomic profiling plus (CGP+) tumor profiling platform report is optimized to molecularly identify and report genomic alterations specifically for the TAPUR Study.
ALEXANDRIA, Va. –The American Society of Clinical Oncology, Inc. (ASCO) and Foundation Medicine today announced entry into an agreement to create efficiencies for research sites participating in ASCO’s TAPUR™ Study in identifying potential participants for the study. ASCO is announcing that reports from Foundation Medicine’s comprehensive genomic profiling (CGP) assays, FoundationOne®, FoundationOne Heme® and FoundationACT® will receive the new “optimized for TAPUR reporting” designation available to entities that demonstrate reporting of nearly 75% of TAPUR-specific genes in a format that meets criteria established for the TAPUR Study. The TAPUR Study is a first-of its-kind clinical trial designed to evaluate molecularly targeted cancer drugs and collect data on clinical outcomes to learn about additional uses of these drugs outside of indications already approved by the Food and Drug Administration.
The American Society of Clinical Oncology (ASCO) congratulates Francis S. Collins, MD, PhD, on the announcement of his continued service as the Director of the National Institutes of Health (NIH). A renowned researcher and skilled administrator, Dr. Collins appreciates the critical role that federal research plays in advancing our understanding of how to prevent, diagnose, and treat cancer and other life-threatening diseases, and has worked tirelessly to ensure that the United States remains at the forefront of biomedical innovation.